Cebi, Ahmet TaylanKasapoglu, Metin Berk2024-09-292024-09-2920211309-3878https://doi.org/10.18521/ktd.772556https://search.trdizin.gov.tr/tr/yayin/detay/427837https://hdl.handle.net/20.500.14619/6957Objective: The aim of this study was to compare the effectiveness of two preemptive sustained-release non-steroidal anti- inflammatory drugs in terms of pain, edema and trismus following third molar surgery. Methods: Overall, 30 patients with double-sided vertically positioned impacted third molars were included in this study. The study was randomized and double- blinded. 30 minutes before the surgery, patients were given sustained-release (SR) dexketoprofen trometamol 75 mg and following the surgery the drug administration continued postoperatively for 1 week, once a day. 2 weeks later, the same procedure was applied for the counterside impacted third molar with 75 mg. sustained-release (SR) diclofenac sodium. The pain was assessed postoperatively by VAS (Visual Analogue Scale) levels at the 6th, 8th, 12th, 24th and 48th hours and on the 3rd, 5th, and 7th days. Edema and trismus measurements were evaluated on the postoperative 2nd and 7th days. Results: There was a statistically significant difference between the groups in VAS levels at 6th, 8th, 12th, 24th, and 48th hours, and on the 3rd and 5th days (P <0.01). Dexketoprofen trometamol SR group had lower VAS levels than diclofenac sodium SR group. There was no statistically significant difference between the groups in terms of mean trismus and edema measurement on the 2nd and 7th days (P<0.05). Conclusions: Dexketoprofen trometamol SR and diclofenac sodium SR are similarly effective for the reduction of edema and trismus following impacted third molar surgery; however, dexketoprofen trometamol SR is found to be more efficient in reducing pain.eninfo:eu-repo/semantics/openAccessThird MolarPostoperative ComplicationsSustained-Release PreparationsNonsteroidal Anti-Inflammatory AgentsArticle10.18521/ktd.7725568818242783713WOS:000628768700013N/A